Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma
- PMID: 10705874
- DOI: 10.3109/07357900009038243
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma
Abstract
Loss of heterozygosity of chromosome 10q has been reported in hepatoma. Areas with a high rate of loss of genetic material could harbor putative tumor suppressor genes. PTEN/MMAC1, a candidate tumor suppressor gene located at chromosome 10q23.3, has recently been identified and found to be homozygously deleted or mutated in several different types of human tumors. To determine whether the PTEN/MMAC1 gene is a target of 10q loss of heterozygosity in hepatoma, we examined 42 primary hepatomas for mutations in PTEN/MMAC1 by using nested reverse transcriptase polymerase chain reaction (RT-PCR) of the RNA and single-stranded conformation polymorphism (SSCP) analysis of all genomic exons. Although 2 of 42 hepatoma tissues had aberrant transcripts, 5 matched noncancerous liver tissues also had aberrant transcripts. Southern blot analysis of the entire genomic DNA revealed no genomic change. Therefore, like the TSG101 or FHIT gene, aberrant transcripts of PTEN/MMAC1 using the nested RT-PCR method were a common phenomenon for both cancerous and noncancerous liver tissues, which may not be related to oncogenesis. None of the 42 cases had small deletions, point mutations, or insertions. Our results suggest that the PTEN/MMAC1 gene may not play a role in the pathogenesis of hepatoma.
Similar articles
-
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer.Gynecol Oncol. 2000 Feb;76(2):193-9. doi: 10.1006/gyno.1999.5659. Gynecol Oncol. 2000. PMID: 10637069
-
PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas.Jpn J Cancer Res. 2000 Mar;91(3):287-92. doi: 10.1111/j.1349-7006.2000.tb00943.x. Jpn J Cancer Res. 2000. PMID: 10760687 Free PMC article.
-
Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia.Am J Hematol. 2000 Apr;63(4):170-5. doi: 10.1002/(sici)1096-8652(200004)63:4<170::aid-ajh2>3.0.co;2-0. Am J Hematol. 2000. PMID: 10706759
-
Are aberrant transcripts of FHIT, TSG101, and PTEN/MMAC1 oncogenesis related?Int J Mol Med. 1999 May;3(5):491-5. doi: 10.3892/ijmm.3.5.491. Int J Mol Med. 1999. PMID: 10202180 Review.
-
PTEN, a unique tumor suppressor gene.Endocr Relat Cancer. 2000 Jun;7(2):115-29. doi: 10.1677/erc.0.0070115. Endocr Relat Cancer. 2000. PMID: 10903528 Review.
Cited by
-
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.Oncotarget. 2012 Mar;3(3):236-60. doi: 10.18632/oncotarget.466. Oncotarget. 2012. PMID: 22470194 Free PMC article. Review.
-
Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma.PLoS One. 2015 May 28;10(5):e0127668. doi: 10.1371/journal.pone.0127668. eCollection 2015. PLoS One. 2015. PMID: 26020957 Free PMC article.
-
Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.Int J Clin Exp Pathol. 2010 May 25;3(5):482-91. Int J Clin Exp Pathol. 2010. PMID: 20606729 Free PMC article.
-
Adenoviral gene therapy in hepatocellular carcinoma: a review.Hepatol Int. 2013 Mar;7(1):48-58. doi: 10.1007/s12072-012-9367-2. Epub 2012 Apr 25. Hepatol Int. 2013. PMID: 26201621
-
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037. Nat Rev Cancer. 2011. PMID: 21430697 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials